Cancer Antigen 72-4 for the Monitoring of Advanced Tumors of the Gastrointestinal Tract, Lung, Breast and Ovaries | Anticancer Research
Tumor markers Flashcards | Quizlet
Doporučené postupy pro časnou detekci, diagnostiku a léčbu jednotlivých stádií karcinomu prostaty
SATB2 is a supplementary immunohistochemical marker to CDX2 in the diagnosis of colorectal carcinoma metastasis in an unknown primary - Dabir - 2018 - APMIS - Wiley Online Library
The prognostic significance of neuroendocrine markers and somatostatin receptor 2 in hepatocellular carcinoma - Murakami - 2021 - Pathology International - Wiley Online Library
Breast Cancer Tumor Markers | GeneTex
Expression of SATB2 in Neuroendocrine Carcinomas of the Lung: Frequent Immunopositivity of Large Cell Neuroendocrine Carcinoma with a Diagnostic Pitfall - Hiromichi Inoue, Jun Matsushima, Satoru Kobayashi, Toshimi Sairenchi, Hirokuni Hirata, Masayuki
Změny dynamiky thymidinkinázy (TK) v průběhu adjuvantní a paliativní chemoterapie kolorektálního karcinomu » Linkos.cz
Oncology
Decipher Test a 4Kscore test v predikcii agresivity karcinómu prostaty v praxi urológa | Unilabs
A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases - Modern Pathology
The application of CA72-4 in the diagnosis, prognosis, and treatment of gastric cancer - ScienceDirect
Normal and abnormal values of cancer marker CA 72-4 | Vinmec
Současné možnosti laboratorního vyšetřování pro onkologicky nemocné 2. část
Tumor Markers - Pathology Made Simple
SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer | Modern Pathology
Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors - Annals of Oncology
PDF) Correlation of Toxicity with Pharmacokinetics of Pegylated Liposomal Doxorubicin (Doxil) in Metastatic Breast Carcinoma
Evaluation of tumor marker cancer antigen 72-4 (CA 72-4) in the monitoring of metastatic or recurrent tumors of the gastrointestinal tract, lung, breast, and ovaries. | Journal of Clinical Oncology
PDF) Correlation of Toxicity with Pharmacokinetics of Pegylated Liposomal Doxorubicin (Doxil) in Metastatic Breast Carcinoma
Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125 - ScienceDirect
